Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT: Avexitide in Postbariatric Hypoglycemia
NCT03373435Phase 2Completed
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of exendin 9-39 in post-bariatric hypoglycemia (PBH) (2 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoint: Postprandial Glucose Nadir. Started Mar 2018; status: completed.
02
Drugs
exendin 9-39
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT03373435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373435.